ProfileGDS5678 / 1424709_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 52% 52% 52% 49% 52% 50% 50% 52% 52% 52% 52% 53% 52% 51% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2999652
GSM967853U87-EV human glioblastoma xenograft - Control 23.2660352
GSM967854U87-EV human glioblastoma xenograft - Control 33.2627552
GSM967855U87-EV human glioblastoma xenograft - Control 43.0964249
GSM967856U87-EV human glioblastoma xenograft - Control 53.2260352
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3011450
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2632550
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2675152
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2450552
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2616252
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2496652
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.24753
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2638552
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2420451